FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
XSWX:SANN'
s FCF Yield % Range Over the Past 10 Years
Min: -255 Med: -26.35 Max: 26.92
Current: -14.71
During the past 13 years, the highest FCF Yield % of Santhera Pharmaceuticals Holding AG was 26.92%. The lowest was -255.00%. And the median was -26.35%.
XSWX:SANN's FCF Yield % is ranked worse than 60.27% of 1417
companies
in the Biotechnology industry
Industry Median: -9.7
vs XSWX:SANN: -14.71
Santhera Pharmaceuticals Holding AG FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Santhera Pharmaceuticals Holding AG FCF Yield % Related Terms
Santhera Pharmaceuticals Holding AG FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG FCF Yield % Chart
XSWX:SANN vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a FCF Yield % of -14.71 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #854 out of 1417 companies in the Biotechnology industry, placing it in the top 60.3%.
Is Santhera Pharmaceuticals Holding AG's FCF Yield % too high?
Santhera Pharmaceuticals Holding AG's current FCF Yield % is -14.71. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #854 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #854 out of 1417 companies for FCF Yield %. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. Santhera Pharmaceuticals Holding AG's current FCF Yield % is -14.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.14, compared to a current price of CHF15.96 — trading 31% below its estimated fair value. The current FCF Yield % is -14.71. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current FCF Yield % is -14.71 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF15.96 is trading 31% below its estimated GF Value™ of CHF23.14.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
FCF Yield %: -14.71
GF Value™: CHF23.14 vs. price of CHF15.96 (31% below fair value)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for XSWX:SANN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
